Comparison of medium-dose losartan/hydrochlorothiazide and maximal-dose angiotensin II receptor blockers in the treatment of Japanese patients with uncontrolled hypertension: the Kobe-CONNECT Study

被引:6
作者
Toh, Ryuji [1 ]
Ishida, Tatsuro
Nishimura, Kunihiro [2 ]
Nonaka, Hidemi [3 ]
Inoue, Yoshimichi [4 ]
Kitagawa, Yasuo [5 ]
Suematsu, Masakuni [6 ]
Miki, Takashi [7 ]
Emoto, Noriaki
Hirata, Ken-ichi [1 ]
机构
[1] Kobe Univ, Grad Sch Med, Dept Internal Med, Div Cardiovasc Med,Chuo Ku, Kobe, Hyogo 6500017, Japan
[2] Kobe Univ, Grad Sch Med, Dept Evidence Based Lab Med, Kobe, Hyogo 6500017, Japan
[3] Konan Hosp, Kobe, Hyogo, Japan
[4] Tatsuno Cent Hosp, Tatsuno, Japan
[5] Yodogawa Christians Hosp, Osaka, Japan
[6] Kobe Century Mem Hosp, Kobe, Hyogo, Japan
[7] Steel Mem Hirohata Hosp, Himeji, Hyogo, Japan
关键词
angiotensin II receptor blockers; diuretics; Japanese; CONVERTING-ENZYME-INHIBITOR; HIGH-RISK PATIENTS; BLOOD-PRESSURE; SALT SENSITIVITY; SYSTOLIC HYPERTENSION; CARDIOVASCULAR EVENTS; CIRCADIAN-RHYTHM; HYDROCHLOROTHIAZIDE; MANAGEMENT; LOSARTAN;
D O I
10.1038/hr.2012.110
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
The objective of this study is to examine the effects of thiazide diuretics, plus medium-dose losartan versus maximal-dose angiotensin II receptor blockers (ARBs) on blood pressure (BP) in Japanese patients with uncontrolled hypertension despite the use of medium-dose ARBs. Hypertensive patients in whom BP was inadequately controlled by treatment with medium-dose ARBs alone or with calcium-channel blockers were enrolled. Patients were randomly assigned to a fixed-dose combination of 50 mg per day losartan and 12.5 mg per day hydrochlorothiazide (HCTZ; n = 98), or to a maximal dose of current ARBs (n = 95). The reduction in office BP from baseline was significantly larger in the losartan/HCTZ group than in the maximal-dose ARB group (systolic BP -22.7 +/- 13.7 vs. -11.7 +/- 13.0 mmHg, diastolic BP -9.6 +/- 10.9 vs. -4.5 +/- 11.0 mmHg; P<0.01, respectively). The proportion of patients in whom the therapeutic target BP was achieved was greater in the losartan/HCTZ group than in the maximal-dose ARB group (59.2 vs. 26.3%; P<0.001). Both early-morning and evening BP were controlled more effectively over 1 year of treatment in the losartan/HCTZ group than in the maximal-dose ARB group (the mean BP difference between the groups, early-morning: 5.6 mmHg (P = 0.001), evening: 3.8 mmHg (P = 0.049)). Adverse changes in serum potassium and uric acid were observed in the losartan/HCTZ group; however, both changes were very slight, and the values were still within the normal range. The concomitant usage of losartan and HCTZ had no influence on glucose metabolism and lipid profiles. Declines in plasma N-terminal pro-brain natriuretic peptide levels and urinary albumin excretion were observed in the losartan/HCTZ group, but not in the maximal-dose ARB group. Switching from medium-dose ARBs to losartan plus HCTZ reduced both office and home BP efficiently in patients with uncontrolled hypertension. Hypertension Research (2012) 35, 1080-1086; doi:10.1038/hr.2012.110; published online 12 July 2012
引用
收藏
页码:1080 / 1086
页数:7
相关论文
共 24 条
  • [21] Efficacy and Safety of a Fixed Combination of Perindopril Arginine and Amlodipine in Patients With Hypertension Uncontrolled by Treatment With Angiotensin II Receptor Blockers in Real Clinical Practice. Results of the PREVOSHODSTVO (SUPERIORITY) Program
    Ostroumova, O. D.
    KARDIOLOGIYA, 2017, 57 (01) : 30 - 36
  • [22] Comparison of the Effect of Combination Therapy with an Angiotensin II Receptor Blocker and Either a Low-Dose Diuretic or Calcium Channel Blocker on Cardiac Hypertrophy in Patients with Hypertension
    Okura, Takafumi
    Miyoshi, Ken-ichi
    Irita, Jun
    Enomoto, Daijiro
    Jotoku, Masanori
    Nagao, Tomoaki
    Watanabe, Kouki
    Matsuoka, Hiroshi
    Ashihara, Toshiaki
    Higaki, Jitsuo
    CLINICAL AND EXPERIMENTAL HYPERTENSION, 2013, 35 (08) : 563 - 569
  • [23] Randomized trial of an increased dose of calcium channel blocker or angiotensin II type 1 receptor blocker as an add-on intensive depressor therapy in type 2 diabetes mellitus patients with uncontrolled essential hypertension: the ACADEMIE Study
    Imaizumi, Satoshi
    Shiga, Yuhei
    Ogawa, Masahiro
    Sako, Hideto
    Nagata, Yoshihisa
    Matsunaga, Akira
    Shirotani, Tetsuro
    Hoshino, Fumihiro
    Yahiro, Eiji
    Uehara, Yuko
    Morito, Natsumi
    Tanigawa, Hiroyuki
    Shimono, Dai
    Fukushima, Mikio
    Sugihara, Hidekazu
    Norimatsu, Kenji
    Kusumoto, Takaaki
    Saku, Keijiro
    Miura, Shin-Ichiro
    Ideishi, Munehito
    Iwata, Atsushi
    Noda, Keita
    Fujimi, Kanta
    Kawamura, Akira
    Adachi, Sen
    Nishikawa, Hiroaki
    Fukushima, Takao
    Tanaka, Nobuhide
    Fujisawa, Kazuhiro
    Takamiya, Yosuke
    Arishima, Hiroaki
    Shimokawa, Toshihiro
    Seto, Hiroshi
    Inoue, Asao
    Midorikawa, Takemasa
    Shijo, Hiroshi
    HEART AND VESSELS, 2019, 34 (04) : 698 - 710
  • [24] Interim evidence of the renoprotective effect of the angiotensin II receptor antagonist losartan versus the calcium channel blocker amlodipine in patients with chronic kidney disease and hypertension: A report of the Japanese Losartan Therapy Intended for Global Renal Protection in Hypertensive Patients (JLIGHT) Study
    Yasuhiko Iino
    Matsuhiko Hayashi
    Tetsuya Kawamura
    Tatsuo Shiigai
    Yasuhiko Tomino
    Kenichi Yamada
    Takeyuki Kitajima
    Terukuni Ideura
    Akio Koyama
    Tetsuzo Sugisaki
    Hiromichi Suzuki
    Satoshi Umemura
    Yoshindo Kawaguchi
    Shunya Uchida
    Michio Kuwahara
    Tsutomu Yamazaki
    Journal of Clinical and Experimental Nephrology, 2003, 7 (3): : 221 - 230